Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
NCT05705492
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) -associated appetite loss while receiving non-curative cancer therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Malignant Solid Neoplasm
- Advanced Biliary Tract Carcinoma
- Advanced Esophageal Carcinoma
- Metastatic Esophageal Carcinoma
- Locally Advanced Colorectal Carcinoma
- Locally Advanced Esophageal Carcinoma
- Locally Advanced Gastric Carcinoma
- Metastatic Colorectal Carcinoma (mCRC)
- Advanced Lung Carcinoma
- Locally Advanced Hepatocellular Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- OHSU Knight Cancer Institute
- Last updated on ClinicalTrials.gov
- July 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Oregon · 1
- OHSU Knight Cancer Institute · Portland, OR
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.